Navigation Links
Intermittent Hormone Treatment for Prostate Cancer Not the Best
Date:4/3/2013

By Randy Dotinga
HealthDay Reporter

WEDNESDAY, April 3 (HealthDay News) -- Advanced prostate cancer patients who are given drugs aimed at lowering their testosterone production to slow the spread of tumors don't get much benefit if the drugs are given only intermittently.

A large international study suggests that the treatment, called intermittent androgen deprivation therapy, may actually do more harm than good, although the numbers are vague and the regimen may temporarily reduce some side effects.

"It's not clear whether there is a benefit to intermittent therapy," said study lead author Dr. Maha Hussain, co-leader of the Prostate Cancer Program at the University of Michigan. However, she added, "in terms of survival, it's not superior."

At issue are patients with prostate cancer that has spread to other parts of the body. Their prognosis is typically grim, and as part of their treatment, many receive hormone-therapy drugs aimed at stopping the body's production of testosterone. The treatment is either continuous or is intermittent to give patients relief from side effects of the therapy.

The treatment, a form of castration via medication, isn't easy to tolerate. It essentially causes a form of male menopause, Hussain said. "You end up getting symptoms that are quite distressing, such as hot flashes, weight gain, reduced muscle mass and impotence, and libido goes down," she said.

But it does slow the spread of the disease in about 90 percent of patients, Hussain said, although at some point most patients become immune to the treatment.

In the new study, researchers analyzed the experiences of more than 1,500 men with newly diagnosed, metastatic, hormone-sensitive prostate cancer, who were assigned to continuous or intermittent treatment with testosterone-lowering drugs and tracked for a median of more than nine years.

Men with a stable or declining PSA level equal to or below a cut-off of 4 ng/ml were randomly assigned to continue or to discontinue the hormone therapy. The therapy was resumed for those in the intermittent group when the PSA climbed to 20 ng/ml.

According to the findings, there was a 10 percent increase in the risk of death with intermittent therapy. Average survival was 5.8 years for the continuous group and 5.1 years for the intermittent group.

But the study called the findings "statistically inconclusive" for figuring out which treatment helps men live longer. And men who took the intermittent treatment did report better quality of life and mental health three months into the study, but not afterward.

Hussain said continuous treatment should remain the standard if the focus is on extending life. But those worried about side effects could still consider the intermittent treatment, she added.

The study, which didn't examine how much each kind of treatment costs, appears in the April 4 issue of The New England Journal of Medicine.

Dr. Bruce Roth, a professor of medicine in the division of oncology at Washington University in St. Louis, said the standard of care should probably remain the continuous approach. Some doctors are currently experimenting with the intermittent approach, he said, although there has been a shortage of high-quality research to support it.

The good news, he said, is that physicians are moving closer to turning prostate cancer into a chronic yet treatable disease, like high blood pressure and diabetes.

More information

For more on prostate cancer, try the U.S. National Library of Medicine.

SOURCES: Maha Hussain, M.D., professor of medicine and urology, associate director for clinical research and co-leader, Prostate Cancer Program, University of Michigan Comprehensive Cancer Center, Ann Arbor; Bruce Roth, M.D., professor of medicine, Division of Oncology, Washington University in St. Louis; April 4, 2013, New England Journal of Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Hormone may help predict tubal ectopic pregnancy
2. New inflammation hormone link may pave way to study new drugs for Type 2 diabetes
3. Dieting May Lower Hormone Levels Tied to Breast Cancer
4. Gum disease joins hot flashes and PMS associated with womens hormones
5. Trivedi Beef, LLC Announces Breakthrough Beef Industry Data without the use of Antibiotic Drugs, Hormones or Steroids
6. Trust hormone oxytocin found at heart of rare genetic disorder
7. Hormone Ratio May Show Which Dieters Will Keep Weight Off
8. 15 top medical organizations agree on hormone therapy use
9. Long-term hormone treatment increases synapses in rat prefrontal cortex
10. Medical Groups Agree on Use of Hormone-Replacement Therapy
11. Force of habit: Stress hormones switch off areas of the brain for goal-directed behaviour
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Intermittent Hormone Treatment for Prostate Cancer Not the Best
(Date:6/27/2017)... ... 2017 , ... Salucro, the cloud-based payment platform that has ... and provider groups, has announced that it will now offer Parasail’s payment plans ... San Francisco health-finance startup that has launched a series of tech-based products that ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the success ... became the sixth state to pass legislation which ensures that children can possess ... Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who have ...
(Date:6/27/2017)... ... , ... A January 18th article on medGadget reports that the ... the year 2024 according to a new report. The article also notes that the ... Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says that it ...
(Date:6/27/2017)... NH (PRWEB) , ... June 27, 2017 , ... ... insurance management assistance and personal financial planning services to residents of southern New ... a charity event that promises to fight hunger and homelessness in the region. ...
(Date:6/27/2017)... Portland, Ore. (PRWEB) , ... June 27, 2017 ... ... Provider (CSP), today announced the expansion of Atmosera Managed Azure Services . ... now includes enhancements in support of the company’s growing customer base. Atmosera’s next ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:6/1/2017)... Pa. , June 1, 2017 Nutriceutical ... and Veterinarian Recommended Solutions (VRS), and KD Pharma Group ... in Nutriceutical Holdings by KD Pharma Group. KD Pharma ... with the option to acquire the entire company. ... in KD. They are committed to growing the NH ...
(Date:5/30/2017)... Israel , May 30, 2017 Therapix ... pharmaceutical Company specializing in the development of cannabinoid-based ... present a company overview at three upcoming scientific ... 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: